证券日报网讯 福瑞达11月26日在互动平台回答投资者提问时表示，针对三季报中化妆品与医药板块营 收短期承压的情况，核心目标是通过业务提质增效修复业绩，切实保障股东长期回报。化妆品板块将聚 焦品牌差异化发展，一方面放大颐莲喷雾品线增长动能，持续通过品牌文化传播与精准营销巩固优势； 另一方面加速瑷尔博士调整见效，通过品线优化（推出益生升级 287 品线、抗衰系列）、全渠道价格管 控及内容创新驱动流量转化，同时推动珂谧等新锐品牌高速放量填补增长缺口。医药板块抢抓药食同源 机遇，依托牵头制定的行业标准，加速 7 款新品市场渗透。同步加码研发投入，综合推进短期业绩提升 与长期可持续发展。 （编辑 楚丽君） ...

Core Insights - The company has shown steady growth in its cosmetics business, with specific brands like Yilian and Kemi demonstrating varying performance levels, while Aier Bozhi has seen a reduction in revenue decline [1][2] Group 1: Revenue Performance - For the first three quarters of 2025, the company's total revenue from cosmetics reached 1.569 billion yuan, a decrease of 8.17%, with Q3 revenue at 475 million yuan, down 9.1% [1] - Yilian's revenue for the first three quarters was 786 million yuan, an increase of 19.5%, with Q3 revenue at 232 million yuan, up 10% [1] - Aier Bozhi's revenue for the first three quarters was 646 million yuan, down 29%, with Q3 revenue at 195 million yuan, down 26%, although the decline has narrowed [1] - Kemi's revenue for the first three quarters was 77.19 million yuan, with a significant Q3 growth rate of 138% [1] Group 2: Profitability and Margins - In Q3 2025, the company reported revenue of 807 million yuan, a decrease of 7.97%, and a net profit attributable to shareholders of 34 million yuan, down 23.07% [2] - The gross profit margin for Q3 was 49.5%, a decline of 2.3 percentage points, primarily due to the drop in cosmetics business margins [2] - The net profit margin attributable to shareholders for Q3 was 4.18%, down 0.83 percentage points, while the adjusted net profit margin was 3.17%, down 1.31 percentage points [2] Group 3: Strategic Focus and Future Outlook - The company is undergoing a business adjustment that is expected to impact short-term profitability, with a focus on the recovery of Yilian and the promising growth of Kemi driven by new technology [2] - Aier Bozhi's revenue decline is expected to stabilize with the introduction of new products, and the management's return to frontline operations is anticipated to enhance the adjustment and recovery of the cosmetics business [2]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a revenue of 2.597 billion yuan for the first three quarters of 2025, a year-on-year decline of 7.3%, and a net profit attributable to shareholders of 142 million yuan, down 17.2% year-on-year. In the third quarter alone, revenue was 810 million yuan, a decline of 7.97% year-on-year, with a net profit of 34 million yuan, down 23.1% year-on-year [2][4]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company's revenue from cosmetics, pharmaceuticals, and raw materials was 1.57 billion yuan, 310 million yuan, and 280 million yuan respectively, with year-on-year changes of -8.2%, -17.5%, and +11.2%. Specifically, the cosmetics segment, led by the brand Yilian, achieved a revenue of 790 million yuan, a growth of 19.5% year-on-year, with the core spray product line seeing a sales increase of 28%. The brand Aier Bo Shi underwent brand adjustments, generating 650 million yuan in revenue, with a narrowing decline in Q3. The brand Kemi accelerated its growth, with revenues of 77.19 million yuan in Q1-Q3, showing sequential growth of 82% and 138% from Q2 to Q3 [10]. Profitability - The company's gross profit margin declined, with the net profit margin decreasing slightly by 0.8 percentage points to 4.2% in Q3 2025. This decline was primarily due to a 2.3 percentage point drop in gross margin attributed to adjustments in the cosmetics business, and an overall increase in sales, management, R&D, and financial expense ratios totaling an increase of 0.9 percentage points [10]. Investment Recommendations - The company is focusing on its core brands in the cosmetics sector, with Yilian showing strong growth. The brand Aier Bo Shi has completed its brand upgrade and product launch, with a narrowing decline. The brand Kemi is also accelerating its growth. The product and brand matrix is gradually improving, which is expected to help restore profitability in the future. The projected EPS for 2025-2027 is 0.24, 0.29, and 0.34 yuan per share respectively [10].

Core Insights - The A-share market saw collective gains on Wednesday, with the Shanghai Composite Index rising by 0.7%, the Shenzhen Component Index by 1.95%, and the ChiNext Index by 2.93%. The total trading volume in the Shanghai and Shenzhen markets reached 22,557.74 billion yuan [2][8] - Key sectors leading the market included power equipment, non-ferrous metals, and non-bank financials, while banks, comprehensive sectors, and food and beverage sectors lagged behind [2][8] - The U.S. stock market showed mixed results, with the Dow Jones Industrial Average down by 0.16%, the S&P 500 unchanged, and the Nasdaq up by 0.55% [2][8] Industry Analysis Capital Market Reform and Long-term Industry Outlook - The ongoing capital market reforms are expected to enhance the long-term fundamentals of the industry. The "15th Five-Year Plan" emphasizes high-quality development, focusing on domestic demand and consumption-driven growth [10][16] - The China Securities Regulatory Commission (CSRC) is implementing measures to protect small investors and optimize the Qualified Foreign Institutional Investor (QFII) system, which is anticipated to benefit the investment banking sector [16][18] - The IPO market is showing signs of recovery, with 78 IPOs raising 77.3 billion yuan in the first three quarters of 2025, marking a year-on-year increase of 13% and 61%, respectively [17][18] Pharmaceutical Industry Focus - The "15th Five-Year Plan" highlights the importance of public health and innovation in the pharmaceutical sector, aiming to improve the healthcare system and promote the development of innovative drugs and medical devices [20][21] - Key initiatives include enhancing the multi-tiered medical insurance system, optimizing drug procurement policies, and promoting the integration of traditional Chinese medicine with modern healthcare practices [21][22] Consumer Goods Sector Performance - The consumer goods sector, particularly in the food industry, is experiencing growth, with companies like Lihai Foods reporting a 14.82% year-on-year increase in revenue for Q3 2025 [27][28] - The company has successfully expanded its product offerings in high-end segments, with significant growth in cream and sauce products, indicating a positive response to its high-end strategy [28][29] Cosmetics Industry Challenges - The cosmetics sector is facing short-term revenue and profit pressures due to product iterations and reduced online traffic, with a reported revenue decline of 7.34% year-on-year for Q1-Q3 2025 [31][32] - Despite these challenges, there is potential for recovery as new products are launched, and the company is focusing on optimizing its product mix to enhance profitability [31][33]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 15% in the next six months [4][14]. Core Insights - The company's revenue and profit have faced short-term pressure due to the core cosmetic products being in a product iteration phase, leading to a year-on-year revenue decline of 7.34% to 2.597 billion yuan and a net profit decline of 17.19% to 142 million yuan for the first three quarters of 2025 [2][4]. - The cosmetic segment is expected to recover as new products gain traction, while the raw materials business is transitioning to higher-end products, which should enhance profit margins [4]. Summary by Sections Revenue and Profit Performance - For the first three quarters of 2025, the company achieved revenue of 2.597 billion yuan, down 7.34% year-on-year, primarily due to the core cosmetic products being in an iteration phase and new product sales not reaching sufficient scale [2]. - The net profit attributable to the parent company was 142 million yuan, a decrease of 17.19% year-on-year [2]. Profitability and Cost Structure - The gross margin for the company decreased by 0.38 percentage points to 51.47%, mainly due to a decline in the gross margin of the cosmetic business [2]. - The net profit margin also fell by 0.61 percentage points to 6.87%, with sales expenses slightly down by 0.08 percentage points to 36.39%, while management and R&D expense ratios increased by 0.63 and 0.77 percentage points, respectively [2]. Future Earnings Forecast - The report adjusts the profit forecast for the company, estimating net profits of 213 million yuan, 254 million yuan, and 292 million yuan for 2025, 2026, and 2027, respectively [4]. - The corresponding price-to-earnings ratios for these years are projected to be 37, 32, and 27 times based on the closing price on October 27, 2025 [4].

Core Insights - The company reported a decline in net profit attributable to shareholders by 23.1% year-on-year for Q3 2025, indicating overall performance pressure [1] - The company focuses on the integration of cosmetic and pharmaceutical sectors, leveraging a "5+N" core technology matrix to enhance future performance [1] Financial Performance - For Q1-Q3 2025, the company achieved revenue of 2.6 billion yuan, down 7.3% year-on-year, with a net profit of 140 million yuan, a decrease of 17.2% [1] - In Q3 alone, revenue was 810 million yuan, down 8.0%, and net profit was 30 million yuan, down 23.1% [1] - The overall gross margin for Q1-Q3 2025 was 51.5%, a slight decrease of 0.4 percentage points [2] Business Segment Analysis - Cosmetics segment revenue was 1.57 billion yuan, down 8.2%, with a gross margin of 61.2%, a decrease of 1.1 percentage points; notable performances included a 19.5% increase in revenue for the Yilian brand [2] - Pharmaceutical segment revenue was 310 million yuan, down 17.5%, but gross margin improved by 1.8 percentage points to 52.3% [2] - Raw materials segment revenue increased by 11.2% to 280 million yuan, with a gross margin of 40.3%, up 0.9 percentage points; pharmaceutical-grade raw material sales surged by 107.8% year-on-year [2] Brand and Strategic Developments - The Yilian brand maintained growth, with a 28% increase in sales for the spray product line in Q1-Q3 2025; a new product launch achieved significant sales during a major shopping event [3] - The company is advancing its raw material strategy, achieving regulatory approvals for new ingredients and enhancing its product offerings in the health and wellness sector [3] - The company is also innovating in traditional Chinese medicine, collaborating with established brands to develop new products [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a decline in net profit of 23.1% year-on-year for Q3 2025, with total revenue for the first three quarters at 2.6 billion yuan, down 7.3% year-on-year. The focus on "cosmeceuticals" and the "5+N" core technology matrix is expected to drive future performance improvements [7] - The company maintains its profit forecast, expecting net profits of 246 million, 287 million, and 329 million yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 0.24, 0.28, and 0.32 yuan [7] - The current price-to-earnings ratio (PE) is projected to be 32.5, 27.9, and 24.3 for the years 2025, 2026, and 2027 respectively [7] Financial Performance Summary - For Q1-Q3 2025, the company achieved revenue of 1.57 billion yuan in the cosmetics segment, down 8.2%, with a gross margin of 61.2%. The pharmaceutical segment generated 310 million yuan, down 17.5%, while the raw materials segment saw revenue of 280 million yuan, up 11.2% [8] - The overall gross margin for the first three quarters was 51.5%, with stable expense ratios for sales, management, and R&D [8] - The company’s brand value has significantly increased, with the "Yilian" brand achieving a valuation exceeding 12 billion yuan, and the launch of new products contributing to sales growth [9] Financial Projections - Revenue projections for the company are as follows: 4.06 billion yuan for 2025, 4.41 billion yuan for 2026, and 4.76 billion yuan for 2027, with expected year-on-year growth rates of 1.9%, 8.5%, and 8.0% respectively [10] - The projected net profit for 2025 is 246 million yuan, with a slight increase to 287 million yuan in 2026 and 329 million yuan in 2027 [10] - The company’s gross margin is expected to remain stable, with projections of 52.5% for 2025, 53.1% for 2026, and 53.6% for 2027 [10]

Core Viewpoint - The company reported its third-quarter financial results for 2025, highlighting a decline in revenue in certain segments while showing growth in others, particularly in the cosmetics sector. The overall financial health remains stable with significant developments in product offerings and market expansion efforts [19]. Financial Performance - For the first nine months of 2025, the company achieved a revenue of 2.597 billion yuan and a net profit attributable to the parent company of 142 million yuan [7]. - The total assets as of September 30, 2025, were 5.831 billion yuan, with net assets attributable to the parent company amounting to 4.187 billion yuan [7]. Segment Performance Cosmetics Segment - The cosmetics segment generated a revenue of 1.569 billion yuan for the first nine months of 2025, representing a year-on-year decline of 8.17%, with a gross margin of 61.24% [7]. - The Yilian brand saw a revenue increase of 19.50%, totaling 786 million yuan, with the spray product line achieving a revenue of 664 million yuan, up 28% [7]. - The Kemi brand experienced significant growth, with a revenue of 77.19 million yuan, showing a quarter-on-quarter increase of 138% in the third quarter [7]. Pharmaceutical Segment - The pharmaceutical segment reported a revenue of 305 million yuan, down 17.46% year-on-year, with a gross margin of 52.27% [8]. - The company developed over 200 new clients across hospital and OTC channels, with 70 new medical institutions added [8]. Raw Materials and Additives Segment - The raw materials and additives segment achieved a revenue of 276 million yuan, reflecting an increase of 11.19% year-on-year, with a gross margin of 40.26% [8]. - The sales volume of pharmaceutical-grade raw materials increased by 107.75% year-on-year [8]. Price Changes Product Prices - The average selling price of skincare products increased by 5.29% year-on-year due to a higher sales proportion of premium products [19]. Raw Material Prices - The average procurement price of packaging materials rose by 6.94% year-on-year, while the price of moisturizing agents decreased by 21.20% year-on-year [20][21]. - The average procurement price of active ingredients decreased by 1.45% year-on-year, while emulsifiers saw a price drop of 3.70% year-on-year [23][26]. Upcoming Events - The company will hold a performance briefing on November 3, 2025, to discuss the third-quarter results and address investor inquiries [12][14].

Core Insights - Furuida Pharmaceutical Co., Ltd. reported a revenue of 2.597 billion yuan and a net profit of 142 million yuan for the first three quarters of 2025, indicating overall performance pressure but signs of recovery in its cosmetics segment [1] Group 1: Cosmetics Business Performance - The cosmetics segment generated revenue of 1.569 billion yuan, a year-on-year decline of 8.17%, but maintained a high gross margin of 61.24%, reflecting strong profitability [1] - The Yilian brand achieved sales of 786 million yuan from January to September, a year-on-year increase of 19.50%, with its core spray product line generating 664 million yuan, up 28%, serving as a key growth driver [1] - The Aier Doctor brand showed signs of recovery with sales of 646 million yuan in the first three quarters, and the decline in the third quarter significantly narrowed [1] Group 2: Brand Development and Market Positioning - Yilian successfully held its first brand culture communication conference, enhancing brand influence and market recognition [1] - Aier Doctor hosted the sixth Microecological Health Conference, reinforcing its research image in the skin microecology field, laying the groundwork for future market recovery [1] Group 3: Emerging Brands and R&D Initiatives - The Koying brand demonstrated high growth potential with sales of 77.19 million yuan in the first three quarters, with sequential growth rates of 82% and 138% in the second and third quarters, respectively [2] - The company continues to invest in R&D, launching the industry's first ideal skin data platform based on ideal skin microbiome research and AI models [2] - The company led the establishment of a group standard for collagen penetration and degradation detection, which has been officially implemented [2] Group 4: Medical Device and Raw Material Performance - The medical device registration progressed with the sodium hyaluronate repair solution receiving product registration, and three Class II medical device certificates obtained in the first three quarters, supporting future expansion in functional skincare and medical aesthetics [2] - The raw materials and additives segment performed steadily, achieving revenue of 276 million yuan, a year-on-year increase of 11.19%, with a gross margin rising to 40.26% [2] - The pharmaceutical segment reported revenue of 305 million yuan, a year-on-year decline of 17.46%, with the company responding by increasing academic promotion and developing new food-medicine homologous products [2]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company reported a revenue of 1.79 billion yuan for H1 2025, a year-on-year decline of 7.05%, and a net profit attributable to shareholders of 110 million yuan, down 15.2% year-on-year [2][4] - In Q2 alone, the company achieved a revenue of 910 million yuan, a decrease of 11.7% year-on-year, with a net profit of 57.25 million yuan, down 16.1% year-on-year [2][4] - The cosmetics business, particularly the Yilian brand, showed steady growth, while the Aier Doctor brand is undergoing a phase of adjustment [10] Summary by Sections Financial Performance - For H1 2025, the cosmetics, pharmaceutical, and raw materials segments generated revenues of 1.09 billion, 210 million, and 180 million yuan respectively, with year-on-year changes of -7.7%, -13.9%, and +4.2% [10] - The Yilian brand achieved a revenue of 550 million yuan, a growth of 23.8% year-on-year, while the Aier Doctor brand saw a revenue decline of 30% to 450 million yuan [10] - The overall gross profit margin slightly improved, with a net profit margin of 6%, down 0.6 percentage points year-on-year [10] Business Segments - The Yilian brand's growth was supported by the announcement of a global spokesperson, leading to a 43% increase in the spray product line [10] - The Aier Doctor brand is in a brand adjustment phase, with new product launches expected to drive future growth [10] - The raw materials business showed stability, with sales of hyaluronic acid reaching 120 million yuan, a year-on-year increase of 23.4% [10] Future Outlook - The company is expected to focus on its main brands, with the Yilian brand showing strong momentum and the Aier Doctor brand undergoing necessary adjustments [10] - The company anticipates improvements in profitability due to optimized channel structures and enhanced gross margins in the raw materials segment [10] - EPS forecasts for 2025-2027 are projected at 0.24, 0.29, and 0.34 yuan per share respectively [10]